Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Accessibility StatementSkip Navigation Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was 15.5 months compared to 9.5 months for the current standard of care Company expects to discuss single-arm accelerated approval study with FDA in Q1 2026 SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), ...